Francois Cedric 4
Accession 0001492422-26-000057
Filed
Jan 22, 7:00 PM ET
Accepted
Jan 23, 4:09 PM ET
Size
9.1 KB
Accession
0001492422-26-000057
Research Summary
AI-generated summary of this filing
Apellis (APLS) CEO Francois Cedric Sells 27,192 Shares
What Happened
Cedric (Francois) Cedric, CEO of Apellis Pharmaceuticals, sold 27,192 shares on January 22, 2026 at $21.77 per share for total proceeds of $591,845. The filing indicates this disposal was to cover tax withholding on restricted stock units (RSUs) released January 21, 2026.
Key Details
- Transaction date: 2026-01-22; Price per share: $21.77; Total value: $591,845.
- Transaction type/code: Sale (S). Footnote indicates sale to cover tax withholding on RSU release (F1).
- Shares owned after transaction: Not specified in the provided filing.
- Trust disclosures: Shares are held in various trusts (The Cedric Francois Irrevocable Trusts of 2023 and related trusts; The Francois Grossi Trust; The Francois‑DuBois Educational Trust) with trustees named; the reporting person disclaims beneficial ownership of trust-held shares except to the extent of pecuniary interest (F2–F5).
- Filing timeliness: Report filed 2026-01-23 for a 2026-01-22 transaction (filed next day), indicating a timely Form 4.
Context
This was a sale to satisfy tax withholding on RSUs — a routine, administrative transaction (often coded F for tax withholding) and not by itself a clear signal of the insider’s view on the company. Multiple holdings are held in trusts with disclaimed beneficial ownership except for pecuniary interest, which is common for estate or tax planning and can affect how ownership is reported.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-01-22$21.77/sh−27,192$591,845→ 286,045 total
- 307,946(indirect: By Trust)
Common Stock
[F2] - 472,065(indirect: By Trust)
Common Stock
[F3] - 300,000(indirect: By Trust)
Common Stock
[F4] - 234,411(indirect: By Trust)
Common Stock
[F5]
Footnotes (5)
- [F1]This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 21, 2026.
- [F2]The securities are held by The Cedric Francois Irrevocable Trust of 2023 - 2. William V. A. Zorn is the trustee of The Cedric Francois Irrevocable Trust of 2023 - 2. The reporting person disclaims beneficial ownership over the shares held by The Cedric Francois Irrevocable Trust of 2023 - 2 except to the extent of his pecuniary interest therein.
- [F3]The securities are held by The Cedric Francois Irrevocable Trust of 2023. William V. A. Zorn is the trustee of The Cedric Francois Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Cedric Francois Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
- [F4]The securities are held by The Francois Grossi Trust, for which Juliana Grossi, the spouse of the reporting person, serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Francois Grossi Trust except to the extent of his pecuniary interest therein.
- [F5]The securities are held by The Francois-DuBois Educational Trust, for which the Fiduciary Trust Company of New England serves as trustee. The reporting person disclaims beneficial ownership over the shares held by The Francois-DuBois Educational Trust except to the extent of his pecuniary interest therein.
Signature
Documents
Issuer
Apellis Pharmaceuticals, Inc.
CIK 0001492422
Related Parties
1- filerCIK 0001658080
Filing Metadata
- Form type
- 4
- Filed
- Jan 22, 7:00 PM ET
- Accepted
- Jan 23, 4:09 PM ET
- Size
- 9.1 KB